MedTrace Logo

PATIENCE Trial: Prospective Algorithm for Treatment of NTM in Cystic Fibrosis

NCT02419989 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 70

Last updated 2024-04-02

No results posted yet for this study

Summary

Isolation of nontuberculous mycobacteria (NTM) from the sputum of individuals with CF is an increasingly common finding, and the lack of an evidenced-based approach to treatment of NTM disease has been identified as one of the greatest unmet needs within the CF community. Current evidence predicts that the prevalence of NTM will remain relatively high in the CF population. Approaches to NTM disease treatment differ widely between centers, and expected outcomes are not known. This study is observational and follows current best practices. The study will help define response to treatment, and collect relevant data associated with treatment of NTM disease to build a framework for future therapeutic trials.

Conditions

Sponsors & Collaborators

  • Cystic Fibrosis Foundation

    collaborator OTHER

  • Children's Hospital Colorado

    collaborator OTHER

  • National Jewish Health

    lead OTHER

Principal Investigators

  • Jerry A Nick, MD · National Jewish Health

  • Stacey Martiniano, MD · Children's Hospital Colorado

Eligibility

Min Age
6 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2025-03-31
Completion
2025-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02419989 on ClinicalTrials.gov